Last updated on December 2018

Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids


Brief description of study

The primary objective of this study is to demonstrate the superior efficacy versus placebo of OBE2109 alone and in combination with add-back therapy for the reduction of heavy menstrual bleeding associated with uterine fibroids in premenopausal women.

Detailed Study Description

The study is a prospective, randomized, parallel group, double-blind, placebo-controlled phase 3 study investigating the efficacy and safety of OBE2109 alone and in combination with add-back therapy for the treatment of uterine fibroids.

Subjects will be randomized to one of 5 treatment groups in a 1:1:1:1:1 ratio.

Clinical Study Identifier: NCT03070899

Contact Investigators or Research Sites near you

Start Over

Chief Medical Officer

Site reference ID 154
Huntington Park, CA United States
3.23miles
  Connect »

Chief Medical Officer

Site reference ID 185
Los Angeles, CA United States
3.23miles
  Connect »

Chief Medical Officer

Site reference ID 184
Cerritos, CA United States
9.29miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.